anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Food neophobia, understood as the rejection of novel foods, is considered one of the biggest barriers to the consumption of fruits and vegetables in preschool children. Some factors like food preferences, gender, genetic characteristics, psychological factors and family factors are also crucial for the acceptance of vegetable in childhood. Some strategies used to modify food preferences of children are repeated exposure and the use of rewards. The aim of this project is to investigate the efficacy of taste exposure-plus small reward in acceptance and consumption of vegetables among preschool children at school. In this context, interventions were attended at school to capture the influence of this environment towards consumption of vegetables among preschool children.

For this, the methodology applied will be a repeated exposure protocol by introducing small rewards to encourage children to taste an unfamiliar or dislike food. Child intake (weight or number of pieces) and liking (hedonic scale) will be assessed at baseline sessions and exposure sessions. Moreover, child's neophobia will be evaluated and additional determinants of child neophobia, such as child's eating behaviour. Quantitative data analysis will be performed by software IBM-SPSS Statistics®. In conducting this research is expected to achieve techniques to overcome neophobia in preschool children and promote vegetable consumption in school and at home. The results may contribute to improve food quality in childhood and consequently in adulthood.
Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
INTRODUCTION: Surgical repair of hiatal hernia (HH) is plagued by high recurrence rates. Hiatoplasty failure has been identified as a major determinant of recurrent symptoms and HH, but there is no consensus on the optimal surgical approach to minimize this complication and hiatal mesh reinforcement remains controversial. The use of the falciform ligament as an autologous rotational flap to support crural repair has been proposed as a potential solution. This review aims to evaluate the safety and efficacy of the falciform ligament flap (FLF) as an adjunct in HH repair.
EVIDENCE ACQUISITION: Searches were conducted on Google, Google Scholar, PubMed, Scopus, Web of Science, and Cochrane through May 2024. The primary study outcome was HH recurrence rate. Secondary outcomes included 30-day mortality rate, postoperative morbidity, and length of hospital stay. Descriptive statistics were used to analyze the data.
EVIDENCE SYNTHESIS: Twelve studies comprising 469 patients undergoing FLF augmentation during primary or revisional HH repair were included. The majority (80.7%) of patients had HH types III-IV. Crural suture hiatoplasty was performed in all cases, and adjunctive mesh reinforcement was reported in two studies. Postoperative morbidity was 4.6%, and there was no mortality. The overall HH recurrence rate was 5.8% (range 0-15.4%).
CONCLUSIONS: Our study seems to suggest that FLF may reduce postoperative HH recurrence. Well designed and comparative studies with long-term follow-up are required to confirm these preliminary data.
This research is being done to learn more about how to help teenagers with a sad or angry mood, and emotional responses out of proportion to what would be expected in a situation. Together these symptoms are called Severe Mood Dysregulation (SMD), a research diagnosis, or disruptive mood dysregulation disorder (DMDD), a newer clinical diagnosis. Currently, there is no standard treatment for teens that have SMD/DMDD. These teens usually receive medication and some type of talk therapy. This research is being done to compare two types of talk therapy to see which is most effective in helping teens with SMD/DMDD. Investigators will compare treatment as usual (TAU) with Interpersonal Psychotherapy for Youth with Mood and Behavior Dysregulation (IPT-MBD). Investigators do not know if TAU and IPT-MBD work just as well, or if one is better than the other. When this study is over, investigators hope there will be a better idea of how to study treatments for teens with SMD/DMDD.

For those participants who receive IPT-MBD, are prescribed an antipsychotic, and have significant improvement in symptoms, investigators will gradually taper the antipsychotic dose.
OBJECTIVES: A survey was conducted to describe the current status of optometric awareness and involvement regarding post-stroke management as literature suggests that visual impairment often goes undiagnosed and unmanaged in stroke survivors.
MATERIALS AND METHODS: A questionnaire was developed by the researchers, pilot tested by 5 other optometric researchers and 15 optometrists and modified based on the feedback. Practicing optometrists were invited to complete the anonymous online survey through optometric organizations in Canada, Hong Kong, India, UK, and US.
RESULTS: Results showed that the majority of optometrists (61%) see 1-5 post-stroke patients per month, although 15% report seeing none. In all cases, optometrists referred stroke patients to other health care professionals more often than receiving incoming referrals from them. About 21% of all respondents were already fully involved in post-stroke vision care and 57% were interested in being more involved. Limiting factors to seeing more post-stroke patients included resources (29.8%), funding (25.8%), awareness (25.1%), and interest (9.8%). There was consensus among respondents in all countries that optometrists should be members of post-stroke care teams.
CONCLUSION: Optometrists are well suited to provide post-stroke visual rehabilitation but are often not included in care teams for these patients. As a result, the visual management of post-stroke patients often is unaddressed.
Participants will receive single dose of 1.5 milligrams (mg) NNC0113-6856 intravenously (i.v.).
<P>PROBLEM TO BE SOLVED: To provide a package equipped with preservation stability and containing a pharmaceutically acceptable granular carrier composition containing iodophor.  <P>SOLUTION: This package is equipped with the preservation stability of a liposome composition containing povidone iodine. The package has a structure of containing the pharmaceutically acceptable granular carrier composition containing the dried iodophor in a bottle or a container formed by a packaging material consisting of a plastic, paper or cardboard. The iodophor consists of a povidone iodine and the liposome composition is formed by lyophilization, etc. The liposome composition contained in the package is stable for a long period, reconstituted by adding a suitable liquid medium and can be made a prepared material suitable for a treatment.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention relates to a traditional Chinese medicine for treating mumps. The traditional Chinese medicine is prepared from, by weight, 3-9 parts of pteris henryi christ, 10-15 parts of michelia yunnanensis, 15-25 parts of paulownia fortunei (Seem.) Hemsl. P.tomentosa (Thunb.) Steud., 5-15 parts of all-grass of manybractelole bugle, 3-6 parts of rhizoma anemones altaicae, two yolks, 3-9 parts of autumn zephyrlily herb, 3-9 parts of ramulus uncariae cum uncis, 3-9 parts of cape jasmine fruit, 5-15 parts of radix paeoniae rubra, 5-15 parts of abroma angusta and 3-9 parts of licorice roots. The traditional Chinese ointment for treating toxin invading heart and liver type mumps takes a traditional theory of traditional Chinese medicine as the basis to conduct the dialectical therapy according to the toxin invading heart and liver type mumps, and the main rules of treatment comprise heat clearing, toxicity removing, liver calming, resuscitation inducing and endogenous wind calming. The drug takes pure traditional Chinese medicines as the raw materials, the medicine is used for external application, toxic and side effects are small, 100-mesh smashing is conducted on the drug, the efficacy is released to a greater extent.
The present study is designed as an open label study of patients with refractory depression and anxiety to evaluate longer term tolerability and early efficacy of transcranial ultrasound treatment. Baseline and outcome measures in this study utilize validated tests that are appropriate for repeated measures which are not affected by practice effects. For patients with refractory depression, the target will be the subgenual cingulate (Brodmann's area 25) through a trans temporal scalp window. For patients with anxiety, the target will be the amygdala. Targeting will include reference to scalp fiducials based on the obtained MRI and Doppler waveform confirmation will be obtained because of the ability of TCD to record Doppler signal from the posterior cerebral artery that runs medial to the mesial temporal lobe.

On the day of the ultrasound appointment, patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the subgenual cingulate or amygdala, depending on the predetermined condition. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space. Patients will undergo 8 total sessions of focused ultrasound. Patients will be evaluated at baseline and upon final ultrasound treatment using the same measures obtained upon entry. Safety and any adverse events will be monitored closely.
A pump for pumping drugs, medicaments or other liquids is disclosed in one embodiment having suture loops co-extensive with the outside surface of the pump. At least one depression is formed in the outside surface of the pump. A wire co-extensive with the outer dimensions of the pump passes over the depression forming a space between the wire and the outside surface of the pump in the depression. In this position, the wire forms a suture loop. The surgeon, when suturing the pump of the present invention in place within a pocket of tissue or other similar location, places a suture between the wire and the outside surface of the pump in the depression to secure the pump. In another embodiment, depressions are created in a pump and a soft material is placed in and attached to the depressions. A suture may then be placed through the material of the soft material and the tissue of the patient in a pocket in the tissue of the patient to affixed the pump in the pocket.
PURPOSE: To elucidate the impact of demographics, including gender, race, ethnicity, and preferred language, on regional visual field (VF) loss and progression in glaucoma.
METHODS: Multivariable linear mixed regressions were performed to determine the impact of race, ethnicity, and preferred language on regional VF loss with adjustment for age and gender. Regional VF loss was defined by pointwise total deviation values and VF loss patterns quantified by an unsupervised machine learning method termed archetypal analysis. All cross-sectional and longitudinal analyses were performed both without and with adjustment for VF mean deviation, which represented overall VF loss severity. P values were corrected for multiple comparisons.
RESULTS: All results mentioned had corrected P values less than 0.05. Asian and Black patients showed worse pointwise VF loss than White patients with superior hemifield more affected. Patients with a preferred language other than English demonstrated worse pointwise VF loss than patients with English as their preferred language. Longitudinal analyses revealed Black patients showed worse VF loss/year compared to White patients. Patients with a preferred language other than English demonstrated worse VF loss/year compared to patients preferring English.
CONCLUSIONS: Blacks and non-English speakers have more severe VF loss, with superior hemifield being more affected and faster VF worsening.
TRANSLATIONAL RELEVANCE: This study furthered our understanding of racial, ethnic, and socioeconomic disparities in glaucoma outcomes. Understanding the VF loss burden in different racial, ethnic, and socioeconomic groups may guide more effective glaucoma screening and community outreach efforts. This research could help reduce vision loss and improve quality of life in disproportionately affected populations by guiding public health efforts to promote glaucoma awareness and access to care.
Patients referred to a tertiary endoscopic resection practice found to have an SSP \>= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
Dopamine agonists, in clinical studies and clinical experience, appear to impair the systemic regulation of blood pressure, with resulting postural hypotension, especially during dose escalation. In addition, patients with Parkinson’s disease appear to have an impaired capacity to respond to a postural challenge. For these reasons, patients being treated with dopaminergic agonists ordinarily (1) require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and (2) should be informed of this risk [see Patient Counseling Information (17.2)].

In a placebo-controlled trial involving patients with advanced Parkinson’s disease, hypotension was reported as an adverse event in 5 of 202 patients (2%) receiving REQUIP XL and in none of the 191 patients receiving placebo. Orthostatic hypotension was reported as an adverse event in 5% of patients receiving REQUIP XL, and in 1% of placebo recipients.

An analysis of the randomized, double-blinded, placebo-controlled study in advanced Parkinson’s disease was conducted using a variety of adverse event terms possibly suggestive of hypotension, including hypotension, orthostatic hypotension, dizziness, vertigo, and blood pressure decreased. This analysis showed a higher incidence of these events with REQUIP XL (7%, 15 of 202) vs. placebo (3%, 6 of 191). This increased incidence was observed in a setting in which patients were very carefully titrated, and patients with clinically relevant cardiovascular disease or symptomatic orthostatic hypotension at baseline had been excluded from this study. 

Orthostatic vital signs (semi-supine to standing) were monitored throughout the study in the advanced Parkinson’s disease study and changes related to REQUIP XL (compared with placebo) from baseline were assessed.

The frequency of any orthostatic hypotension at any time during the study was 38% for REQUIP XL vs. 31% for placebo for mild to moderate systolic blood pressure decrements (≥20 mm Hg), 63% for REQUIP XL vs. 58% for placebo for mild to moderate diastolic blood pressure decrements (≥10 mm Hg), 10% for REQUIP XL vs. 7% for placebo for severe diastolic blood pressure decrements (≥20 mm Hg), and 23% for REQUIP XL vs. 19% for placebo for mild to moderate combined systolic and diastolic blood pressure decrements.

Significant decrements in blood pressure unrelated to standing were also reported in some patients taking REQUIP XL. In the semi-supine position, the frequency was 10% for REQUIP XL vs. 8% for placebo for severe systolic blood pressure decrease (≥40 mm Hg), and was 25% for REQUIP XL vs. 21% for placebo for severe diastolic blood pressure decrease (≥20 mm Hg). 

The increased incidence for hypotension and/or orthostatic hypotension was observed in both the titration and maintenance phases and in some cases persisted into the maintenance period after developing in the titration phase.
Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (\<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed (\<200 c/mL) HIV-1 infected adults (18 years or older) who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care. IMPALA seeks to demonstrate the non-inferior antiviral effectiveness of switching to long acting injectable rilpivirine (RPV LA) plus long acting injectable cabotegravir (CAB LA) given every 2 months (Q2M CAB LA + RPV LA) by IM compared to the continuation of first-line daily oral ART containing 2 nucleoside reverse transcriptase inhibitor (NRTIs) plus an integrase strand transfer inhibitor (INSTI; dolutegravir \[DTG\]).

After providing written informed consent, participants will be evaluated for eligibility during the screening period. Participants who are viremic (HIV VL \>200 c/mL) at the time of screening will be virologically suppressed (for \>3 months) on a regimen of 2 NRTIs plus DTG prior to randomization. On Day 1 virologically suppressed (\<200 c/mL for at least 3 months) individuals will be randomized 1:1 to either continue daily oral ART (2 NRTI + DTG, control arm), or switch to Q2M CAB LA + RPV LA IM, the intervention arm. Those randomized to the intervention arm will be offered either optional oral lead-in (OLI) of 1 month daily oral CAB and RPV or a direct to injection (DTI) approach. This decision to dose with or without an OLI Phase will be determined by the study participant following the informed consent discussion with the investigator. The total duration of the study will be 24 months. Any participant who has received at least a single dose of CAB LA + RPV LA and discontinues the regimen for any reason before Month 24 must start suppressive daily oral ART within 2 months of the last injection. There will be an optional real-world extension phase, provided the regimen is deemed to be non-inferior at Month 12 and 24.
Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
Participants consumed 8 capsules of sodium butyrate per day for a week. The capsules were consumed with main meals (2 for breakfast, 2 for lunch and 2 for dinner). Each capsule contained 200 mg of sodium butyrate, for a total of 1.6 grams of sodium butyrate per day.
PROBLEM TO BE SOLVED: To obtain a new safe hair-growing agent excellent in the hair-growing effect and capable of being sufficiently used over a long period by using an extract obtained from a specific plant belonging to the family Leguminosae. SOLUTION: This hair-growing agent contains an extract obtained by extracting Bauhinia variegata, a small tree belonging to the genus Bauhinia in the family Leguminosae, originated in the Southeast Asia with a water-soluble organic solvent or a water-containing organic solvent. The content of the extract is preferably 0.001-10wt.%, especially 0.05-5wt.%. When the hair-growing agent contains a skin peripheral vasodilator in addition to the extract of the Bauhinia variegata, the hair-growing agent exhibits a more preferable hair-growing effect. The skin peripheral vasodilator includes carpronium chloride, benzyl nicotinate, vitamin E, and vitamin E acetate. The hair-growing agent can be prepared in the forms such as hair tonic, shampoo, hair rinse, pomade, hair lotion and hair cream.
In the volatile group, anesthesia is maintained with inhaled sevoflurane and intermittent cisatracurium doses. Cisatracurium is repeated based on TOF ratio, and anesthesia depth is controlled by BIS, maintaining values between 25 and 50. Drug doses are adjusted according to TOF and BIS values.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by left ventricular (LV) hypertrophy. There is often associated LV diastolic dysfunction and myocardial ischemia. The severity of the LV hypertrophy, diastolic dysfunction, and myocardial ischemia are important determinants of clinical outcomes. Angiotensin II modulates cell growth and cardiac function. There is also increasing evidence that the renin-angiotensin system (RAS) may be present in cardiac cells, and the hypertrophic action of angiotensin II could therefore be mediated by circulating or locally produced hormone. Animal and clinical studies have demonstrated that independent of their effects on systemic blood pressure, ACE inhibition and angiotensin II receptor (AT1) blockade can reduce cardiac hypertrophy, improve LV diastolic function and myocardial ischemia. AT1 blockade may be preferable to ACE inhibitors because by inhibiting angiotensin II from binding to its receptor, the system can be turned off irrespective of the source of angiotensin II. Also, there may be fewer side effects due to lack of bradykinin. This is a double-blind, placebo-controlled study that examines the abilities of enalapril (ACE inhibition) and losartan (AT1 blockade), separately or in combination, to cause regression of the cardiac hypertrophy, and to improve LV function and myocardial perfusion in non-obstructive HCM.
Natural hemodynamic changes after balloon pulmonary artery angioplasty (BPA) in a unified state without oxygen administration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) remains undetermined. This study aimed to clarify the delayed changes in the hemodynamics after BPA in patients with CTEPH. We analyzed 73 consecutive patients with CTEPH who underwent BPA between July 2014 and December 2022. We extracted and evaluated hemodynamic data of the right heart catheter without oxygen administration immediately before and after the first BPA; and immediately before the second BPA, as the "post-delayed changes" after BPA. BPA significantly improved the mean pulmonary artery pressure (mPAP, mmHg) and pulmonary vascular resistance (PVR, dyn-s/cm5) from 36 (32-43) mmHg and 449 (312-627) dyn-s/cm5 before the first BPA to 28 (23-32) mmHg and 275 (217-366) dyn-s/cm5 immediately after BPA, and further significantly improved the values to 23 (20-28) mmHg and 225 (175-301) dyn-s/cm5 post-delayed changes after BPA, respectively. Improvement observed on account of delayed changes was observed both with and without pulmonary hypertension drugs. The delayed changes were observed during a period of 5-180 days, which did not correlate with the changes in mPAP and PVR. Hemodynamic improvement owing to BPA was observed immediately after BPA; however, further improvement was observed as a result of delayed changes. mPAP improved by 3.4 ± 5.2 mmHg and PVR by 53 (10-99) dyn-s/cm5 as delayed improvement. mPAP and PVR showed delayed improved by approximately 10% of their values before BPA.